Comparative Pharmacokinetic–Pharmacodynamic Evaluation of L-Theanine and L-Leucine Polymeric Nanoparticles in a Paracetamol-Induced Hepatic Injury Model
Abstract
Background: Polymeric nanoparticle systems can modify the disposition and release characteristics of bioactive molecules and may improve their biological performance. The present work compared the in-vivo pharmacokinetic and hepatoprotective responses of optimized L-theanine- and L-leucine-loaded polymeric nanoparticles. Methods: Optimized formulations LT-SE-PN4 and LL-SE-PN4, prepared by the solvent evaporation approach, were selected for in-vivo evaluation. Their reported particle sizes were 127.21 ± 1.11 nm and 126.11 ± 1.09 nm, respectively, with entrapment efficiencies of 85.17 ± 0.30% and 81.37 ± 0.80%. Pharmacokinetic profiles were assessed following oral administration in albino rats. Hepatic effects were evaluated using serum AST, ALT, ALP and bilirubin, absolute liver weight and histopathological examination in a paracetamol-associated hepatic injury model. Results: LT-SE-PN4 produced a Cmax of 1.54 ± 0.42 µg/mL at 4 ± 0.08 h, whereas LL-SE-PN4 produced a Cmax of 2.98 ± 0.74 µg/mL at 2 ± 0.06 h. Reported AUC0–24 values were 22.36 ± 2.21 and 41.56 ± 2.78 µg/mL·h, with relative bioavailability values of 319.92% and 320.91%, respectively. Disease-control animals showed increased AST, ALT, ALP, bilirubin and absolute liver weight. Both nanoparticle-treated groups showed biochemical values closer to the normal-control group and comparatively preserved liver histology. Conclusion: The present work derived in-vivo findings demonstrate a consistent association between nanoparticle administration, altered systemic exposure and improved biochemical and histological indices in the experimental hepatic injury model. The findings support further controlled pharmacokinetic, mechanistic, toxicological and translational studies of these formulations.
Keywords: L-theanine; L-leucine; polymeric nanoparticles; pharmacokinetics; hepatoprotection; paracetamol; liver injury; bioavailability.
Keywords:
L-theanine, L-leucine, polymeric nanoparticles, pharmacokinetics, hepatoprotection, paracetamol, liver injury, bioavailabilityDOI
https://doi.org/10.22270/jddt.v16i10.8050References
1. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-20. https://doi.org/10.1016/S0168-3659(00)00339-4 PMid:11166403
2. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):701-5. https://doi.org/10.1016/j.addr.2011.12.006 PMid:22210134 PMCid:PMC3323692
3. Crucho CI. Stimuli-responsive polymeric nanoparticles for nanomedicine. ChemMedChem. 2015;10(1):24-38. https://doi.org/10.1002/cmdc.201402290 PMid:25319803
4. Iversen TG, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today. 2011;6(2):176-85. https://doi.org/10.1016/j.nantod.2011.02.003
5. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887-913. https://doi.org/10.1016/j.progpolymsci.2011.01.001
6. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18. https://doi.org/10.1016/j.colsurfb.2009.09.001 PMid:19782542
7. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26:1025-1058. https://doi.org/10.1007/s11095-008-9800-3 PMid:19107579
8. Marin E, Briceño MI, Caballero-George C. Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine. 2013:3071-3091. https://doi.org/10.2147/IJN.S47186 PMid:23990720 PMCid:PMC3753153
9. Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505-5616. https://doi.org/10.1021/acs.chemrev.3c00705 PMid:38626459 PMCid:PMC11086401
10. Elmowafy M, Shalaby K, Elkomy MH, Alsaidan OA, Gomaa HA, Abdelgawad MA, et al. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. Polymers (Basel). 2023;15(5):1123. https://doi.org/10.3390/polym15051123 PMid:36904364 PMCid:PMC10007077
11. Tehrani SF, Bharadwaj P, Chain JL, Roullin VG. Purification processes of polymeric nanoparticles: how to improve their clinical translation? J Control Release. 2023;360:591-612. https://doi.org/10.1016/j.jconrel.2023.06.038 PMid:37422123
12. Cai Y, Nie T, Luo X, Wu Y, Wu J. Nanotechnology-driven biomaterials for chronic liver diseases: stage-specific strategies for advanced theranostics. Acta Biomater. 2026;212:103-123. https://doi.org/10.1016/j.actbio.2026.01.043 PMid:41581743
13. Mohamed NA, Atifi F, Ourradi Z, Crovella S, Derbala M, Yassine HM, et al. Nanoparticle approaches for hepatitis therapy and clinical translation. Discover Nano. 2026;21:31. https://doi.org/10.1186/s11671-026-04450-8 PMid:41649705 PMCid:PMC12881238
14. Tolani SL, Soni S. Drug delivery to the liver using nanocarriers: current trends and future perspectives. Curr Drug Deliv. 2026. Early View. https://doi.org/10.2174/0124681873448306260209073248
15. Nasir A, Kausar A, Younus A. A review on preparation, properties and applications of polymeric nanoparticle-based materials. Polym Plast Technol Eng. 2015;54(4):325-341. https://doi.org/10.1080/03602559.2014.958780
16. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26:1025-1058. https://doi.org/10.1007/s11095-008-9800-3 PMid:19107579
17. Zhang Q, Chuang KT. Adsorption of organic pollutants from effluents of a kraft pulp mill on activated carbon and polymer resin. Adv Environ Res. 2001;5:251-258. https://doi.org/10.1016/S1093-0191(00)00059-9
18. Bilati U, Allémann E, Doelker E. Sonication parameters for the preparation of biodegradable nanocapsules of controlled size by the double emulsion method. Pharm Dev Technol. 2003;8(1):1-9. https://doi.org/10.1081/PDT-120017517 PMid:12665192
19. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm. 2007;336(2):367-375. https://doi.org/10.1016/j.ijpharm.2006.11.061 PMid:17207944
20. Ashjari M, Khoee S, Mahdavian AR. Controlling the morphology and surface property of magnetic/cisplatin-loaded nanocapsules via W/O/W double emulsion method. Colloids Surf A Physicochem Eng Asp. 2012;408:87-96. https://doi.org/10.1016/j.colsurfa.2012.05.035
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Pushpendra Kumar , Suman Shrivastava
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.